Evidence map›Paper›PMID 32899974›Full record

ArticleCancers2020

pT1 Colorectal Cancer Detected in a Colorectal Cancer Mass Screening Program: Treatment and Factors Associated with Residual and Extraluminal Disease.

Joaquín Cubiella, Antía González, Raquel Almazán, Elena Rodríguez-Camacho, Juana Fontenla Rodiles, Carmen Domínguez Ferreiro, Coral Tejido Sandoval, Cristina Sánchez Gómez, Natalia de Vicente Bielza, Isabel Peña-Rey Lorenzo and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04821258 (Double-blind Randomized Clinical Trial to Evaluate the Effect of the Nutraceutical "MICODIGEST 2.0" on the Complications After Surgery With Curative Intent for Colorectal Cancer), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04821258 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Double-blind Randomized Clinical Trial to Evaluate the Effect of the Nutraceutical "MICODIGEST 2.0" on the Complications After Surgery With Curative Intent for Colorectal Cancer

TypeinterventionalSponsorFundacin Biomedica Galicia SurRan2021 to 2022Enrolled144ConditionsColorectal Cancer, Surgery--ComplicationsArmsMICODIGEST 2.0 supplement, Placebo supplement
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Joaquín CubiellaDepartment of Gastroenterology, Hospital Universitario de Ourense, Rúa Ramón Puga 52-56, 32003 Ourense, Spain.ORCID 0000-0002-9994-4831
Antía GonzálezDepartment of Preventive Medicine, Hospital Universitario de Ourense, 32003 Ourense, Spain.
Raquel AlmazánDirección Xeral de Saúde Pública, Conselleria de Sanidade, 15781 Santiago de Compostela, Spain.
Elena Rodríguez-CamachoDirección Xeral de Saúde Pública, Conselleria de Sanidade, 15781 Santiago de Compostela, Spain.
Juana Fontenla RodilesDirección Xeral de Saúde Pública, Conselleria de Sanidade, 15781 Santiago de Compostela, Spain.
Carmen Domínguez FerreiroDirección Xeral de Saúde Pública, Conselleria de Sanidade, 15781 Santiago de Compostela, Spain.
Coral Tejido SandovalDepartment of Gastroenterology, Hospital Universitario de Ourense, Rúa Ramón Puga 52-56, 32003 Ourense, Spain.
Cristina Sánchez GómezDepartment of Gastroenterology, Hospital Universitario de Ourense, Rúa Ramón Puga 52-56, 32003 Ourense, Spain.
Natalia de Vicente BielzaDepartment of Gastroenterology, Hospital Universitario de Ourense, Rúa Ramón Puga 52-56, 32003 Ourense, Spain.
Isabel Peña-Rey LorenzoDirección Xeral de Saúde Pública, Conselleria de Sanidade, 15781 Santiago de Compostela, Spain.
Raquel ZubizarretaDirección Xeral de Saúde Pública, Conselleria de Sanidade, 15781 Santiago de Compostela, Spain.
Conselleria de Sanitat Universal i Salut Pública · ESComplejo Hospitalario de Ourense · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ES

Funding

Academia Médico Quirúrgica of Ourense 2018-2020Instituto de Salud Carlos III PI17/00837
6 · The paper itself

Abstract

The aim of this study is to describe the treatment of pT1 colorectal cancer (CRC) in a mass screening program, the surgery-related complications and the factors associated with residual disease after endoscopic resection and extraluminal disease after surgery. We included in this retrospective analysis all the pT1 CRC detected in the Galician CRC screening program between May 2013 and June 2019. We determined which variables were independently associated with the outcomes of the study through a multivariable logistic regression analysis. We included 370-354 pT1 N0(X), 16 pT1N1- out of the 971 CRC detected; 277 (74.9%) were resected endoscopically and 162 (43.8%) were not referred to surgery. There were surgical complications in 30.7% and 16.3% of the patients during hospitalization and after discharge. Residual disease was detected in 12 (4.3%) after endoscopic resection and extraluminal disease in 18 (8.6%) patients after surgery. The variables independently associated with initial endoscopic resection were a pedunculated morphology (OR 33.1, 95% CI 4.3-254), a diameter ≥ 20 mm (OR 3.94, 95% CI 1.39-11.18) and a Site-Morphology-Size-Access score < 9 (OR 428, 95% CI 42-4263). The variables related with surgery rescue were a piecemeal resection (OR 4.48, 95% CI 1.48-13.6), an infiltrated/nonevaluable resection border (OR 7.44, 95% CI 2.12-26.0), a non-well-differentiated histology (OR 4.76, 95% CI 1.07-20.0), vascular infiltration (OR 8.24, 95% CI 2.72-25.0) and a Haggitt 4 infiltration of the submucosa (OR 5.68, 95% CI 2.62-12.3). Residual disease after endoscopic resection was associated with an infiltrated/nonevaluable resection border (OR 34.9, 95% CI 4.08-298), a non-well-differentiated histology (OR 6.67, 95% CI 1.05-50.0), and the vascular infiltration of the submucosa (OR 7.61, 95% CI 1.55-37.4). The variables related with extraluminal disease after surgical resection were no endoscopic resection (OR 4.34, 95% CI 1.26-14.28), a non-well-differentiated histology (OR 4.35, 95% CI 1.39-14.29) and the lymphatic infiltration of the submucosa (OR 4.8, 95% CI 1.32-17.8). In a CRC screening program, although most of pT1 CRC are candidates for endoscopic treatment, surgery is a safe procedure. We have defined some easy to evaluate variables that can be used in the decision-making process.

Indexed as

colorectal cancerendoscopic resectionovertreatmentpT1screeningside effects

Identifiers

PMID32899974
PMCPMC7565413
OpenAlexW3083588152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.